Advances in the Treatment of Hemophilia: Clinical Gene Therapy
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
All articles by Caleb Rans, PharmD
The Role of Immune Checkpoint Inhibitors in Treating Hematologic Malignancies
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
A Novel Screening Program for Severe Combined Immunodeficiency in Newborns
Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.
Clinical Management of Diamond-Blackfan Anemia in Children
Despite deeper understanding of some of the molecular mechanisms underlying Diamond-Blackfan anemia, the search for effective therapies is ongoing.
Clinical Management of Non-Graft-Versus-Host Disease Ocular Complications Following Hematopoietic Cell Transplantation
Non-GVHD ocular complications can seriously affect patient morbidity and quality of life following hematopoietic cell transplantation.
Improving the Clinical Diagnosis of Inherited Bleeding Disorders
Many unique challenges surround the diagnosis and treatment of inherited mild bleeding disorders.
Can Modifying Microbial Diversity Change Outcomes Following Allogeneic HSCT?
Some studies have found a link between intestinal microbiota composition and development of acute graft-versus-host disease.
Clinical Significance of Aspirin and NSAID Antiplatelet Interactions
Concomitant use of aspirin and NSAIDs gives rise to a pharmcodynamic interaction that may interfere with aspirin’s antiplatelet effects.
Prognostic Value of Minimal Residual Disease in Indolent Lymphomas
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Novel Management Strategies for Myeloma Bone Disease
Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.
Next post in Myeloma
